Jiangsu Hengrui Medicine Co., Ltd.

This study tests whether a combination of two drugs (camrelizumab and apatinib) can help people with advanced stomach or gastroesophageal junction cancer live longer compared to standard chemotherapy. The trial includes 550 adults whose cancer progressed after first-line platinum…

This study tests a new drug called SHR-A1811 in 60 women with advanced cervical cancer that has come back or spread and no longer responds to standard therapy. The drug targets a protein called HER2 on cancer cells. The main goal is to see if tumors shrink. Participants must be 1…

This study tests a new drug called HRS-4357 against current standard treatments for men with a type of advanced prostate cancer that has spread and no longer responds to hormone therapy. About 370 men will be randomly assigned to receive either HRS-4357 or another drug to see whi…

This study tests a new drug called HRS-6768 in people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can help control the disease. About 84 participants will be enrolled in this early-phase trial.

This early-phase study tests a new drug called HRS-6093 in 153 adults with advanced solid tumors that have a specific KRAS G12D mutation. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. Participants must have tried standard tr…

This study tests a pill called hetrombopag to see if it can safely raise platelet counts in cancer patients whose platelets drop too low after chemotherapy. About 150 adults with solid tumors (like lung, breast, or colon cancer) will receive either the drug or a placebo during th…

This study tests a new treatment for advanced neuroendocrine tumors of the gut and pancreas that cannot be removed by surgery. About 220 adults will receive either a radioactive drug (lutetium-177) plus standard-dose long-acting octreotide, or high-dose octreotide alone. The goal…

This study tests a new drug, trastuzumab rezetecan, against an approved drug, trastuzumab deruxtecan, in 150 women with a specific type of advanced breast cancer (HR-positive, HER2-low) that cannot be removed by surgery. The goal is to see if the new drug works better at slowing …

This study tests a new medicine called SHR0302, given as a pill alone or with a gel, for people with non-segmental vitiligo (white patches on skin). The goal is to see if it can bring back skin color safely. About 176 adults aged 18-75 will take part. The study is in phase 2, mea…

This study tests a new drug called HRS-6209 combined with other treatments for breast cancer. About 80 women whose cancer has worsened after prior therapy will receive the combination. The goal is to check safety, find the best dose, and see if it helps shrink tumors.

This study tests a new drug called SHR-A1904 in people with advanced solid tumors, specifically stomach or pancreatic cancer that has not responded to other treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 83 adults will take part in th…

This study tests a new drug, SHR-A1811, combined with either pyrotinib or SHR-1316 in people with advanced HER2-positive non-small cell lung cancer. The goal is to see if these combinations are safe and can shrink tumors. About 324 adults aged 18-75 with good performance status a…

This study tests a new drug called HRS-9190 against an existing one (cisatracurium) to keep muscles relaxed during surgery. About 60 adults having planned surgery will take part. The goal is to see how quickly muscle function returns after the drug is stopped, and to check for si…

This study tests a new drug called HRS-8364 in people with advanced solid tumors that have not responded to standard treatments. The trial has three stages to find the safest dose and check if the drug shrinks tumors. About 282 adults aged 18-75 will take part.

This study tests a new drug called SHR2554 against an existing drug, chidamide, for people with a rare blood cancer (PTCL) that has returned or not responded to prior therapy. About 130 adults aged 18-70 will be randomly assigned to one of the two treatments. The main goal is to …

This study tests a new drug called SHR-4394 combined with other cancer treatments for men with prostate cancer. The goal is to find a safe dose and see if it lowers PSA levels, a marker of cancer activity. About 100 men aged 18 to 85 with advanced prostate cancer will take part. …

This study tests a new drug called FH-006 in 200 women aged 18-75 with advanced solid tumors that have worsened after standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors. Participants will be closely monitored for side effects and immune…

This study tests a new pill called HRS-5041 combined with other cancer treatments for men with advanced prostate cancer that has spread or stopped responding to standard therapy. About 100 men aged 18-80 will participate to find the best dose and see if the combo can shrink tumor…

This study tests a new drug, HRS-9190, against a standard muscle relaxant (rocuronium) during surgery. About 90 adults having planned surgery will receive one of the two drugs. The main goal is to see how quickly muscle function returns after the last dose, with safety also monit…

This study tests a new drug (HRS-1167) combined with two standard treatments (abiraterone and prednisone) in 66 men with metastatic prostate cancer. The goal is to find the safest dose and see if the combination helps control the cancer. Participants must have confirmed prostate …

This study tests whether adding a new drug (SHR4640) to a standard gout medication (febuxostat) works better than increasing the dose of febuxostat alone for people with gout and high uric acid. About 340 adults whose uric acid is still too high on 40 mg of febuxostat will take e…

This study tests a new drug called FH-006 combined with other cancer treatments for people with advanced non-small cell lung cancer. The goal is to find the safest dose and see if the combination shrinks tumors. About 200 adults aged 18-75 with measurable tumors and good organ fu…

This study tests a new drug called SHR-A1811 in 300 people with ovarian, fallopian tube, or primary peritoneal cancer that no longer responds to platinum-based chemotherapy. Participants will receive either SHR-A1811 or a standard chemotherapy chosen by their doctor. The main goa…

This study tests a new drug called SHR2554, taken as a tablet, combined with other cancer treatments for people with advanced non-small cell lung cancer that has spread. The goal is to see if the combination is safe and can shrink tumors. About 200 adults aged 18-75 with good org…

This study tests a new drug called SHR-A1811 against a standard combination of chemotherapy and targeted drugs for women with early-stage or locally advanced HER2-positive breast cancer. About 740 participants will receive either the new drug or the standard treatment before surg…

This study is for people with advanced solid tumors that have a specific genetic mutation called KRAS G12D. The trial tests a new drug, HRS-4642, combined with other anti-cancer medicines to see if it is safe and helps shrink tumors. About 118 adults aged 18 to 75 with good perfo…

This study tests two experimental drugs (HS-20093 or SHR2554) taken with standard hormone therapy in men with metastatic prostate cancer. The goal is to see if these combinations can lower PSA levels and control the cancer. About 218 men aged 18 to 80 with advanced disease will p…

This study tests a new drug called HRS-4508 in 120 people with advanced non-small cell lung cancer that has stopped responding to standard treatments. The main goals are to see if the drug shrinks tumors and to check for side effects. Participants must be between 18 and 80 years …

This study tests a new drug called HRS-4508 combined with other cancer treatments for people with advanced non-small cell lung cancer that has not responded to standard therapy. About 100 adults aged 18-75 will participate to find the best dose and check safety. The goal is to se…

This phase 3 study tests whether a new drug called rezvilutamide, combined with hormone therapy, works better than the current standard enzalutamide plus hormone therapy for men with low-volume metastatic hormone-sensitive prostate cancer. About 206 participants will receive one …

This study tests a new drug, SHR-A1811, against standard treatments for people with advanced or spreading non-small cell lung cancer that has a specific change called a HER2 mutation. About 300 adults who have not had prior treatment for their advanced cancer will receive either …

This phase 3 trial compares a new chemotherapy combination (irinotecan liposome plus oxaliplatin, 5-FU, and calcium folinate) against the current standard (nab-paclitaxel plus gemcitabine) for people with metastatic pancreatic cancer who have not yet received treatment. The study…

This study tests a drug called herombopag to safely increase platelet counts in people with chronic liver disease who need surgery. Low platelets raise bleeding risks, and this treatment aims to reduce the need for platelet transfusions. About 101 adults with mild to moderate liv…

This early-stage study tests a new injection called SHR-3167 in 55 adults with type 2 diabetes. The goal is to see how the drug moves through the body and how well it controls blood sugar. Participants will be monitored for side effects and low blood sugar events.

This study tests a new drug, SHR2554, combined with other cancer treatments for people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if the combination is safe and helps shrink tumors or slow the dise…

This early-stage study tests a new drug called HRS-7172 in people with advanced solid tumors that have RAS gene mutations or amplifications. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 120 adults aged 18-75 with good…

This early-stage study tests a new injection called SHR-1049 in 200 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. Participants will be closely monito…

This early-stage study tests a new drug called HRS-2329 in people with advanced solid tumors that have RAS mutations or amplifications. The main goals are to check safety, find the best dose, and see how the drug moves through the body. About 120 adults aged 18-75 who have tried …

This study tests a drug called remimazolam to sedate children and teens during surgery. It aims to see if it works well and is safe. About 240 kids and teens having planned surgery will take part.

This study tests a new, long-lasting form of the painkiller bupivacaine (given as a shot near the spine) to see how well it controls pain after lung surgery done with a tiny camera. About 96 adults having a lung lobe removed will be enrolled. The goal is to find the best dose tha…

This study tests a new sedative called tegileridine fumarate for patients in the intensive care unit (ICU) who need a breathing machine (ventilator) for 2 to 3 days. The goal is to keep patients calm and comfortable while on the ventilator. About 120 adults will take part, and th…

This study looks at whether a special long-acting numbing medicine (bupivacaine liposome) can safely control pain in children after orthopedic surgery. About 232 kids aged 6 to 17 will receive the injection at the surgical site. Researchers will track side effects and how much ex…

This early-phase study tests the safety and tolerability of a new injectable drug called HRS-2183 in 42 healthy Chinese adults aged 18-45. Participants receive either a single dose or multiple doses to see how the drug moves through the body and if it causes any side effects. The…